Catapres-tts-3 and Atenolol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Catapres-tts-3 and Atenolol. Common interactions include blood phosphorus decreased among females and markedly reduced food intake among males.

The phase IV clinical study analyzes what interactions people who take Catapres-tts-3 and Atenolol have. It is created by eHealthMe based on reports of 10 people who take Catapres-tts-3 and Atenolol from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Sep, 22, 2022

10 people who take Catapres-tts-3 and Atenolol together, and have interactions are studied.


What is Catapres-tts-3?

Catapres-tts-3 has active ingredients of clonidine. eHealthMe is studying from 150 Catapres-tts-3 users for its effectiveness, alternative drugs and more.

What is Atenolol?

Atenolol has active ingredients of atenolol. It is often used in high blood pressure. eHealthMe is studying from 166,879 Atenolol users for its effectiveness, alternative drugs and more.

Number of Catapres-tts-3 and Atenolol reports submitted per year:

Catapres-tts-3 and Atenolol drug interactions.

Common Catapres-Tts-3 and Atenolol drug interactions by gender *:

female:

  1. Blood phosphorus decreased
  2. Blood potassium decreased
  3. Blood sodium decreased
  4. Chest pain
  5. Diarrhoea
  6. Haemoglobin decreased
  7. Haemorrhoidal haemorrhage
  8. Haemorrhoids
  9. Headache
  10. Hyponatraemia

male:

  1. Markedly reduced food intake
  2. Stevens johnson syndrome

Common Catapres-Tts-3 and Atenolol drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Headache
  2. Hyponatraemia

50-59:

n/a

60+:

  1. Cerebrovascular accident
  2. Application site burning
  3. Chest pain
  4. Diarrhoea
  5. Haemoglobin decreased
  6. Haemorrhoidal haemorrhage
  7. Haemorrhoids
  8. Markedly reduced food intake
  9. Monoplegia
  10. Muscle spasms

Common conditions people have *:

  1. Bipolar Disorder (mood disorder): 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Catapres-tts-3 and Atenolol?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Catapres-tts-3 and Atenolol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Atenolol interactions:

Browse all interactions between Atenolol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on clonidine and atenolol (the active ingredients of Catapres-tts-3 and Atenolol, respectively), and Catapres-tts-3 and Atenolol (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Catapres-tts-3 and Atenolol.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: